ALKS · Categories · Conferences
ALKS - Conference and earnings call announcements
Alkermes plc (ALKS) conference and earnings call announcements - real-time wire coverage filtered to Conferences only.
Recent Conferences for ALKS
- Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare ConferenceAlkermes plc (NASDAQ:ALKS) announced today that management will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Wednesday, June 10, 2026 at 10:00 a.m. ET (3:00 p.m. BST). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plc Alkermes plc (NASDAQ:ALKS), a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. A
- Alkermes to Present at the Stifel 2026 Virtual CNS ForumAlkermes plc (NASDAQ:ALKS) announced today that management will participate in a fireside chat at the Stifel 2026 Virtual CNS Forum on Tuesday, March 17, 2026 at 8:30 a.m. ET (12:30 p.m. GMT). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plc Alkermes plc (NASDAQ:ALKS), a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Alkermes' pipeline includes
- Alkermes to Present at the TD Cowen 46th Annual Health Care ConferenceAlkermes plc (NASDAQ:ALKS) announced today that management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 9:10 a.m. ET (2:10 p.m. GMT). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plc Alkermes plc (NASDAQ:ALKS), a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Alkermes' pipeli
- Alkermes to Present at the 44th Annual J.P. Morgan Healthcare ConferenceAlkermes plc (NASDAQ:ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 44th Annual J.P. Morgan Healthcare Conference. The presentation will take place on Tuesday, Jan. 13, 2026 at 10:30 a.m. PST (1:30 p.m. EST/6:30 p.m. GMT). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plc Alkermes plc (NASDAQ:ALKS), a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dep
- Alkermes to Participate in Two Upcoming Investor ConferencesAlkermes plc (NASDAQ:ALKS) announced today that management will participate in two upcoming investor conferences. 8th Annual Evercore Healthcare Conference Date/Time: Wednesday, Dec. 3, 2025 at 2:10 p.m. ET (7:10 p.m. GMT) Piper Sandler 37th Annual Healthcare Conference Date/Time: Thursday, Dec. 4, 2025 at 12:00 p.m. ET (5:00 p.m. GMT) The live webcasts may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plc Alkermes plc (NASDAQ:ALKS), a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commerci
- Alkermes to Participate in Two Upcoming Investor ConferencesDUBLIN, Nov. 6, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) announced today that management will participate in two upcoming investor conferences. Stifel 2025 Healthcare ConferenceDate/Time: Thursday, Nov. 13, 2025 at 2:40 p.m. ET (7:40 p.m. GMT) Jefferies Global Healthcare Conference in LondonDate/Time: Wednesday, Nov. 19, 2025 at 11:30 a.m. ET (4:30 p.m. GMT) The live webcasts may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plcAlkermes plc (NASDAQ:ALKS), a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio
- Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare ConferenceDUBLIN, June 2, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) announced today that management will participate in a fireside chat presentation at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 10:00 a.m. EDT (3:00 p.m. BST). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plc Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of c
- Alkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences– Multiple Subgroup Analyses Presented From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan), Including Data on Lipid and Glycemic Profiles – DUBLIN, June 2, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced the presentation of accepted research at key scientific conferences this spring, including presentations largely related to its psychiatry products LYBALVI® (olanzapine and samidorphan) and ARISTADA® (aripiprazole lauroxil). Several of these meetings coincided with Mental Health Awareness Month in May, an important moment to raise awareness about mental health conditions, support the millions of people living with these complex diseases, and acknowledge the c
- Alkermes to Participate in the 24th Annual Needham Virtual Healthcare ConferenceDUBLIN, April 2, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) announced today that management will participate in a webcast panel discussion "Development of Orexin Receptor Agonist in Sleep-Wake Disorders" at the upcoming 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025 at 11:45 a.m. EDT (4:45 p.m. BST). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plcAlkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioi
- Alkermes to Participate in Upcoming Investor ConferencesDUBLIN, Feb. 26, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) announced today that management will participate in webcast fireside chats at two upcoming investor conferences. TD Cowen 45th Annual Health Care ConferenceDate/Time: Wednesday, March 5, 2025 at 9:50 a.m. ET (2:50 p.m. GMT) Leerink Partners Global Healthcare Conference 2025Date/Time: Wednesday, March 12, 2025 at 11:20 a.m. ET (3:20 p.m. GMT) The live webcasts may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plcAlkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of propri
- Alkermes to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceDUBLIN, Jan. 2, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation will take place on Wednesday, Jan. 15, 2025 at 11:15 a.m. PST (2:15 p.m. EST/7:15 p.m. GMT), followed by a question and answer session. The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plcAlkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for
- Alkermes to Participate in Upcoming Investor ConferencesDUBLIN, Nov. 25, 2024 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) announced today that management will participate in two upcoming investor conferences. 7th Annual Evercore ISI HealthCONx ConferenceDate/Time: Tuesday, Dec. 3, 2024 at 10:25 a.m. ET (3:25 p.m. GMT) Piper Sandler 36th Annual Healthcare ConferenceDate/Time: Wednesday, Dec. 4, 2024 at 4:00 p.m. ET (9:00 p.m. GMT) The live webcasts may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plcAlkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for th
- Alkermes to Participate in Two Upcoming Investor ConferencesDUBLIN, Nov. 11, 2024 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) announced today that management will participate at two upcoming investor conferences. Stifel Healthcare ConferenceDate/Time: Monday, Nov. 18, 2024 at 8:35 a.m. ET (1:35 p.m. GMT) Jefferies London Healthcare ConferenceDate/Time: Tuesday, Nov. 19, 2024 at 8:00 a.m. ET (1:00 p.m. GMT) The live webcasts may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plcAlkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol depen
- Alkermes to Host Investor Event to Review Orexin Portfolio StrategyDUBLIN, Sept. 25, 2024 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) announced today that it will host an investor event for financial analysts and institutional investors on Wednesday, Oct. 9, 2024 starting at 10:00 a.m. EDT in Waltham, Mass. Members of Alkermes' Research & Development team will review the company's orexin portfolio and development strategy. The event will also feature a clinician and thought leader panel discussion. A question and answer session will follow the presentations. The event will also be available virtually via webcast. Registration for the webcast is available on the Investors section of the company's website at www.alkermes.com. To ensure a timely connection, it
- Alkermes to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry ConferenceDUBLIN, Sept. 19, 2024 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) announced today that management will participate in a fireside chat presentation at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Conference on Thursday, Sept. 26, 2024 at 9:20 a.m. EDT (2:20 p.m. BST). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plcAlkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and
- Alkermes to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceDUBLIN, Aug. 28, 2024 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) announced today that management will participate in a fireside chat presentation at the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, Sept. 4, 2024 at 2:35 p.m. EDT (7:35 p.m. BST). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plcAlkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline
- Alkermes to Participate in Two Upcoming Investor ConferencesDUBLIN, May 29, 2024 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) announced today that management will participate in fireside chat presentations at two upcoming investor conferences. Jefferies Healthcare ConferenceDate/Time: Thursday, June 6, 2024 at 1:30 p.m. EDT (6:30 p.m. BST) Goldman Sachs 45th Annual Global Healthcare ConferenceDate/Time: Tuesday, June 11, 2024 at 10:40 a.m. EDT (3:40 p.m. BST) The live webcasts may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plcAlkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary c
- Alkermes to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceDUBLIN, Jan. 3, 2024 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 42nd Annual J.P. Morgan Healthcare Conference. The presentation will take place on Wednesday, Jan. 10, 2024 at 11:15 a.m. PST (2:15 p.m. EST/7:15 p.m. GMT), followed by a question and answer session. The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plcAlkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for
- Alkermes to Participate in Two Upcoming Investor ConferencesDUBLIN, Nov. 21, 2023 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) announced today that management will participate in fireside chat presentations at two upcoming investor conferences. Piper Sandler 35th Annual Healthcare Conference Date/Time: Tuesday, Nov. 28, 2023 at 11:00 a.m. ET (4:00 p.m. GMT) 6th Annual Evercore ISI HealthCONx Conference Date/Time: Wednesday, Nov. 29, 2023 at 10:00 a.m. ET (3:00 p.m. GMT) The live webcasts may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plcAlkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of pr
- Alkermes to Participate in Two Upcoming Investor ConferencesDUBLIN, Sept. 5, 2023 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) announced today that management will participate in fireside chat presentations at two upcoming investor conferences. Morgan Stanley 21st Annual Global Healthcare Conference Date/Time: Monday, September 11, 2023 at 11:20 a.m. EDT (4:20 p.m. BST) Cantor Fitzgerald Global Healthcare Conference Date/Time: Wednesday, September 27, 2023 at 11:30 a.m. EDT (4:30 p.m. BST) The live webcasts may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plc Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and o
- Alkermes to Participate in Two Upcoming Investor ConferencesDUBLIN, May 31, 2023 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) announced today that management will participate in fireside chats at two upcoming investor conferences. Jefferies Healthcare ConferenceDate/Time: Wednesday, June 7, 2023 at 10:00 a.m. EDT (3:00 p.m. BST) Goldman Sachs 44th Annual Global Healthcare ConferenceDate/Time: Monday, June 12, 2023 at 9:20 a.m. PDT (12:20 p.m. EDT/5:20 p.m. BST) The live webcasts may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plcAlkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a por
- Alkermes Highlights Data From Psychiatry Portfolio at Spring 2023 Scientific Conferences̶ Clinical and Patient Experience Research Delivers Insights into Treatment for People Living with Schizophrenia or Bipolar I Disorder ̶ DUBLIN, May 16, 2023 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced the presentation of research related to its psychiatry portfolio—which includes LYBALVI® (olanzapine and samidorphan) and ARISTADA® (aripiprazole lauroxil)—at four scientific conferences this spring. Several of these meetings coincide with Mental Health Awareness Month in May, an important moment in the year that provides an opportunity to raise awareness about mental health conditions, support the millions of people living with these complex diseases, and acknowledge the crit
- Alkermes to Participate in the Stifel 2023 CNS DaysDUBLIN, March 15, 2023 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) announced today that management will participate in a fireside chat as part of the Stifel 2023 CNS Days on Wednesday, March 29, 2023 at 9:00 a.m. ET (2:00 p.m. BST). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plc Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in de
- Alkermes to Present at the 41st Annual J.P. Morgan Healthcare ConferenceDUBLIN, Dec. 28, 2022 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 41st Annual J.P. Morgan Healthcare Conference. The presentation will take place on Wednesday, Jan. 11, 2023 at 11:15 a.m. PST (2:15 p.m. EST/7:15 p.m. GMT), followed by a question and answer session. The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plc Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary c
- Alkermes to Participate in the BofA Securities 2022 Biotech SMID Cap ConferenceDUBLIN, Nov. 30, 2022 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) announced today that management will participate in a fireside chat as part of the BofA Securities 2022 Biotech SMID Cap Conference on Wednesday, Dec. 7, 2022 at 8:00 a.m. ET (1:00 p.m. GMT). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plc Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline o
- Alkermes to Participate in the 5th Annual Evercore ISI HealthCONx ConferenceDUBLIN, Nov. 22, 2022 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) announced today that management will participate in a fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on Tuesday, Nov. 29, 2022 at 2:40 p.m. ET (7:40 p.m. GMT). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plcAlkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product cand
- Alkermes to Participate in the Stifel Healthcare ConferenceDUBLIN, Nov. 8, 2022 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) announced today that management will participate in a fireside chat at the Stifel 2022 Healthcare Conference on Tuesday, Nov. 15, 2022 at 8:00 a.m. ET (1:00 p.m. GMT). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plc Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in de
- Alkermes to Participate in the Goldman Sachs Healthcare ConferenceDUBLIN, June 8, 2022 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) announced today that management will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Wednesday, June 15, 2022 at 2:40 p.m. PT (5:40 p.m. ET/10:40 p.m. BST). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plcAlkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a
- Alkermes to Participate in the Jefferies Healthcare ConferenceDUBLIN, June 1, 2022 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) announced today that management will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 2:30 p.m. ET (7:30 p.m. BST). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plcAlkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in deve
- Alkermes to Participate in the Stifel 2022 CNS DaysDUBLIN, March 22, 2022 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) announced today that its Chief Executive Officer, Richard Pops, will participate in a fireside chat at the Stifel 2022 CNS Days on Tuesday, March 29, 2022 at 8:30 a.m. ET (1:30 p.m. BST). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plcAlkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of pro
- Alkermes to Present New Research From Psychiatry and Addiction Portfolios at Upcoming Scientific ConferencesDUBLIN, Oct. 29, 2021 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced plans to present research from its psychiatry and addiction portfolios at upcoming scientific conferences this fall. The meetings include: Psych Congress (Oct. 29-Nov. 1, San Antonio and virtual); International Society for Affective Disorders (ISAD) Conference (Nov. 3-4, virtual); Neuroscience Education Institute (NEI) Congress (Nov. 4-7, Colorado Springs, Colo. and virtual). "Alkermes has been at the forefront of developing medicines in the fields of psychiatry and addiction for many years, and we remain committed to helping people living with these serious, chronic diseases," said Craig Hopkinson, M.D., Chief
- Alkermes to Take Part in the Citi Annual BioPharma Virtual ConferenceDUBLIN, Sept. 2, 2021 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) announced today that management will participate in a fireside chat at the Citi 16th Annual BioPharma Virtual Conference on Thursday, Sept. 9, 2021 at 8:50 a.m. ET (1:50 p.m. BST). The presentation may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plc Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for
- Alkermes Announces Recipients of 2021 Alkermes Inspiration Grants® ProgramDUBLIN, July 23, 2021 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced the 2021 recipients of grants from the company's signature Alkermes Inspiration Grants® program. Grants were awarded to 11 nonprofit organizations working to address the needs of people living with addiction, serious mental illness or cancer, including programs serving historically under-resourced or underrepresented communities, including Black, Indigenous and people of color (BIPOC), LGBTQ+ individuals, veterans, women and people impacted by the U.S. criminal justice system. "Now in its fifth year, the Alkermes Inspiration Grants program exemplifies our long-standing commitment to supporting organizations tha
- Alkermes Presents New Data on Nemvaleukin Alfa at 2021 American Society of Clinical Oncology Annual MeetingDUBLIN, June 4, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced new data from its ARTISTRY clinical development program for nemvaleukin alfa (nemvaleukin), Alkermes' novel, investigational engineered interleukin-2 (IL-2) variant immunotherapy. The data are being presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place virtually June 4-8, 2021, and in an investor webcast presentation hosted by the company. The presentations include updated efficacy and safety data from ARTISTRY-1, an ongoing phase 1/2 study investigating intravenous (IV) nemvaleukin, which showed anti-tumor activity of IV nemvaleukin monotherapy in checkpoint inhibitor
- Alkermes Announces FDA Approval of LYBALVI™ for the Treatment of Schizophrenia and Bipolar I DisorderDUBLIN, June 1, 2021 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced that the U.S. Food and Drug Administration (FDA) has approved LYBALVI™ (olanzapine and samidorphan) for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. LYBALVI is a once-daily, oral atypical antipsychotic composed of olanzapine, an established antipsychotic agent, and samidorphan, a new chemical entity. "Schizophrenia and bipolar I disorder are complex, chronic diseases and there remains a persistent need for new medications w
- Alkermes to Present at the 39th Annual J.P. Morgan Healthcare ConferenceDUBLIN, Jan. 6, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 39th Annual J.P. Morgan Healthcare Conference. The presentation will take place virtually on Wednesday, Jan. 13, 2021 at 10:00 a.m. EST (3:00 p.m. GMT), followed by a question and answer session. The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plc Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary co